

JC687 U.S. PTO
08/10/00

08-11-00

A

Please type a plus sign (+) inside this box → ☒

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))</small>	Attorney Docket No.	GER-100XC1
	First Inventor or Application Identifier	Gerber, John F.
	Title	Materials and Methods for the Efficient Production of Pasteuria
	Express Mail Label No.	EK507535834US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original and a duplicate for fee processing)</small>	5. <input type="checkbox"/> Microfiche Computer Program (Appendix)
2. <input checked="" type="checkbox"/> Specification [Total Pages 22] <small>(preferred arrangement set forth below)</small> <ul style="list-style-type: none">- Descriptive title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R & D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claim(s)- Abstract of the Disclosure	6. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small> <ul style="list-style-type: none">a. <input checked="" type="checkbox"/> Computer Readable Copyb. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)c. <input checked="" type="checkbox"/> Statement verifying identity of above copies
3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets]	
4. Oath or Declaration [Total Pages X] <ul style="list-style-type: none">a. <input checked="" type="checkbox"/> Newly executed (original or copy)b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d)) <small>(for continuation/divisional with Box 16 completed)</small><ul style="list-style-type: none">i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).	

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ACCOMPANYING APPLICATION PARTS	
7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))	
8. <input type="checkbox"/> 37 C.F.R. § 3.73(b) Statement (when there is an assignee)	<input type="checkbox"/> Power of Attorney
9. <input type="checkbox"/> English Translation Document (if applicable)	
10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/> Copies of IDS Citations
11. <input type="checkbox"/> Preliminary Amendment	
12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small>	
13. <input checked="" type="checkbox"/> * Small Entity Statement(s) filed in prior application, (PTO/SB/09-12) Status still proper and desired	
14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	
15. <input checked="" type="checkbox"/> Other: Claims the benefit of USSN 60/148,154; filed August 10, 1999	

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

<input type="checkbox"/> Continuation	<input type="checkbox"/> Divisional	<input type="checkbox"/> Continuation-in-part (CIP)	of prior application No: _____
Prior application information: Examiner _____		Group / Art Unit: _____	

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS			
<input type="checkbox"/> Customer Number or Bar Code Label		<input type="checkbox"/> Correspondence address below	
<div style="text-align: center;">23557</div>			
PATENT TRADEMARK OFFICE			
Name			
Address			
City	State	Zip Code	
Country	Telephone	Fax	

Name (Print/Type)	David R. Saliwanchik	Registration No. (Attorney/Agent)	31,794
Signature	David Saliwanchik	Date	Aug. 10, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

FEE TRANSMITTAL FORM

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of:

Inventor(s): John F. Gerber and James H. White

Entitled: Materials And Methods For The Efficient Production Of *Pasteuria*

- A Utility Patent Application Transmittal Form accompanies this Fee Transmittal Form.
- The filing fee is calculated below:

CLAIMS AS FILED				
	Number filed	Number Extra	Rate	Fee
Basic Fee				\$ 345.00
Total Claims	30 - 20 =	10	-0- x \$09	99.00
Independent Claims	5 - 3 =	2	-0- x \$39	78.00
Presentation of Multiple Dependent Claim(s) (\$165)				0
Total Filing Fee				\$ 522.00

- Please charge \$522.00 to Deposit Account No. 19-0065. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any additional filing fees which may be required, or credit any overpayment, to Deposit Account No. 19-0065. A duplicate copy of this sheet is enclosed.
- This application is being mailed by Express Mail under 37 CFR 1.10 and the required certificate appears below.

August 10, 2000
Date

David Salivanchil
Attorney of Record

CERTIFICATE OF MAILING BY EXPRESS MAIL (37 CFR 1.10)

Express Mail No. EK507535834US Date of Deposit: August 10, 2000

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Shannon Audette
Name of person mailing paper

Shannon Audette
Signature

Applicant or Patentee: John F. Gerber and James H. White Attorney's
Serial No.: _____ Docket No. GER-100XC1
Filed: _____
For: Materials And Methods For The Efficient Production Of *Pasteuria*

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9 (f) and 1.27 (c)) – SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN Entomos LLC
ADDRESS OF CONCERN 4445 S.W. 35th Terrace, Suite 310
Gainesville, FL 32608

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9 (d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled

Materials And Methods For The Efficient Production Of *Pasteuria*

by inventor(s) John F. Gerber and James H. White

described in:

- ☐ the specification filed herewith
☐ application serial no. _____, filed _____
☐ patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9 (d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9 (d) or a nonprofit organization under 37 CFR 1.9 (e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring their status as small entities. (37 CFR 1.27)

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change of status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28 (b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING _____
TITLE OF PERSON OTHER THAN OWNER James H. White
ADDRESS OF PERSON SIGNING 4445 S.W. 35th Terrace, Suite 310
Gainesville, FL 32608
SIGNATURE _____ DATE _____

DESCRIPTIONMATERIALS AND METHODS FOR
THE EFFICIENT PRODUCTION OF *PASTEURIA*

5

Cross-Reference to Related Application

This application claims the benefit of U.S. Provisional Application No. 60/148,154, filed August 10, 1999.

10

Background of the Invention

This invention relates to methods for the production of *Pasteuria*, or *Pasteuria*-like, bacteria. These bacteria are able to produce endospores that have the unique and useful property of being able to attach to, infect, grow in, re-sporulate in, and kill certain types of phytopathogenic nematodes and other soil-dwelling nematodes.

15

Crop losses due to phytopathogenic nematodes exact a heavy toll in US agriculture. For 1994, Koenning *et al.* (*Nematology* 31:587-618, 1999) estimate losses due to nematodes to be in excess of \$1.5 billion for corn, soy, wheat, cotton, peanut and vegetable combined. These phytopathogenic nematodes come from the phylum *Nematoda*, within the orders *Tylenchida* and *Dorylamidae*. Expenditures in the US for fumigants and nematicides on these and other crops totaled just over \$400 million in 1996 (Chemical Economics Handbook, SRI International, 1997).

20

25

Phytopathogenic nematodes are particularly difficult to control because they are covered with a thick, impermeable cuticle, or outer covering, and have very few sensory neurons. Since many pest control compounds operate as neurotoxins, the low number of neurons exposed by phytopathogenic nematodes decreases the effective target area for nematicidal compounds and has resulted in the development of nematicidal compounds with exquisitely high neurotoxic properties. Furthermore, because the phytopathogenic nematodes are found in soil or plant roots, exposing the phytopathogenic nematodes to control agents also is difficult to achieve and puts the water table at risk of contamination

from those toxic compounds. The use of nematicides based on neurotoxins has been demonstrated to contaminate both ground and surface water. Consequently, many of these compounds are being removed from the market for public health reasons.

Fumigation of soil prior to planting is a popular method for controlling nematodes. One of the most popular fumigants, methyl bromide, is slated for removal from use because of its ozone destroying properties. However, this practice of soil fumigation kills organisms in soil indiscriminately and runs the risk of eliminating beneficial microbes as well as disease organisms. The overall market for an effective nematicide with benign environment effects is estimated to approach one billion dollars on a world-wide basis.

Pasteuria was first described in 1888 by Mechnikoff (Annales de l'Institut Pasteur 2:165-170) as a parasite of water fleas. Subsequently, Cobb described a *Pasteuria* infection of the nematode *Dorylaimus bulfiferous* (2nd ed. Hawaiian Sugar Planters Assoc., Expt. Sta. Div. Path. Physiol. Bull. 5:163-195, 1906). In the intervening years, *Pasteuria* infections of virtually every known nematode have been observed, and their potential for use in biological control of phytopathogenic nematodes has been noted (Chen and Dickson [1998] *J. Nematology* 30:313-340).

Although bacteria of the *Pasteuria* group have a recognized potential for use as biorational control agents against phytopathogenic nematodes, their widespread use in commercial agriculture will depend on the availability of reliable methods for the large-scale production of bacteria having specificity against the phytopathogenic nematodes of concern to farmers.

Previous attempts at *in vitro* culture of *Pasteuria* used vegetative phase tissue recovered from infected females which were surface disinfected with materials such as "Clorox" and were cultured with antibiotics to avoid contamination. Rich media such as Graces Insect Media, Schneiders Insect Media, or Leibovitz Insect Media were used and supplemented with numerous materials, see (Bishop and Ellar).

Most of the experimental work with the *Pasteuria* group of bacteria has used spores produced in live nematodes, cultivated on whole plants in greenhouses where aseptic conditions do not prevail. In two exceptions, Verdeho *et al.* (Verdeho, S. and R. Mankau

[1986] *Journal of Nematology* 18:635) have reported on the oligoxenic culture of *Pasteuria penetrans* in live *Meloidogyne incognita* on excised tomato root culture; and Reise *et al.* (Reise, R. W., K.J. Hackett, R.M. Sayre, and R.N. Huettel [1988] Abstracts of the 27th Annual Meeting Society of Nematologists, p. 75) have studied factors in various tissue culture media affecting *Pasteuria* isolates from *Heterodera glycines*, *Meloidogyne incognita*, and *Pratylenchus brachyurus*. Their attempts are directed at a genuine *in vitro* cultivation of *Pasteuria*, which attempts fail on the basis of the fundamental criterion that a genuine *in vitro* cultivation of any prokaryotic organism must be marked by a continual survival and proliferation of the organisms, upon transfer to a fresh medium, at some definable growth rate that is characteristic of the genotype of the organism and the environmental conditions.

U.S. Patent No. 5,094,954 describes an alternative method for producing endospores from *Pasteuria* by growing the bacteria on explanted nematode tissue. In the method of U.S. Patent No. 5,094,954, the nematode tissue may be prepared, for example, by decapitating and decaudating nematodes, or by osmotic and/or enzymatic disruption of the nematode cuticle. The nematode tissue is explanted onto media which is designed to nourish the tissue and keep it in a metabolically active state. The tissue is then induced into growth and cell proliferation. Thus, this method does not rely on *in vitro* cultivation of the *Pasteuria*, but is directed at the production of *Pasteuria* spores on explanted or cultured nematode tissue.

Thus, although *Pasteuria* was first reported as far back as 1888, all attempts to culture the microbe *in vitro* have failed to produce a viable means of producing endospores. Therefore, there remains in this art a great need for a method of producing *Pasteuria* by spore formation following true *in vitro* growth of the vegetative phase of *Pasteuria* on an artificial growth medium consisting of inexpensive, readily available materials. Such systems are not known at this time.

Brief Summary of the Invention

The subject invention provides novel and advantageous methods for growing bacteria. The methods of the subject invention are particularly advantageous for growing parasitic bacteria, *in vitro*, without the presence of host tissue. In one embodiment of the

subject invention, *Pasteuria* spores, such as those that infect the rootknot nematode *Meloidogyne arenaria* or other host nematodes, are grown *in vitro*. The process of the subject invention is highly advantageous because *Pasteuria* can be grown in the absence of nematode tissue.

5 The bacteria spores obtained using the methods of the subject invention can then be used in any appropriate composition or process. This greatly simplifies the process and reduces material and labor costs. Specifically exemplified herein is the production of *Pasteuria* endospores and the use of these spores in nematode control programs.

10 In a specific embodiment of the subject invention, the growth of *Pasteuria* is carried out on agar plates or in liquid. Also, preferably, no antibiotic or bleach is added to the growth medium.

15 Advantageously, the method of the subject invention results in growth of bacterial mass and an increase in the number of cellular units of the vegetative stage of the bacteria. Subsequently, sporulation occurs from the late vegetative phase of the bacteria with production of mature, dormant spores. In the case of *Pasteuria*, the spores are infective for nematodes, including *Meloidogyne arenaria* and other nematode species.

20 A further aspect of the subject invention concerns the identification of helper factor(s) which, when present in *Pasteuria* growth medium, facilitate the *in vitro* growth of the *Pasteuria*. In one embodiment, the helper factor is a microorganism. A specific isolate of this helper factor has been deposited with the American Type Culture Collection and has been assigned the deposit number ATCC _____. In a further embodiment, the helper factor is a chemical compound which, when present in the *Pasteuria* growth medium, facilitates the *in vitro* growth of *Pasteuria*. Specifically exemplified herein is the helper factor designated HF-1 which can be obtained from the culture designated ATCC _____.

25 Further aspects of the subject invention include compositions comprising *Pasteuria* endospores and the use of these compositions to control phytopathogenic nematodes.

 Another aspect of the subject invention pertains to the use of the helper factors described herein to promote the growth of *Pasteuria* in or around plants thereby controlling nematodes.

Brief Description of the Sequence

SEQ ID NO. 1 shows a polynucleotide sequence of a helper factor bacteria according to the subject invention.

5

Detailed Disclosure of the Invention

10

The subject invention provides methods for the efficient production of bacterial spores. Specifically exemplified herein is the *in vitro* production of *Pasteuria* endospores. In accordance with the subject invention, *Pasteuria* are grown and produce endospores that have the unique and useful property of being able to attach to, infect, grow in, re-sporulate in, reduce the fecundity of, and/or kill certain types of phytopathogenic nematodes and other soil-dwelling nematodes. In addition, *Pasteuria* can reduce the ability of nematodes to infect plants.

15

In one aspect, the subject invention provides a method for producing endospores of parasitic bacteria species *in vitro* without the presence of living host tissue. These parasitic bacteria include, for example, various bacillus species. In a preferred embodiment, a *Pasteuria* production process of the subject invention involves the use of a helper factor such as, for example, a second bacterium or a chemical factor produced by a second bacterium. This method is highly advantageous because it requires only simple growth media which is, preferably, not stirred or mixed and has no antibiotics added. No nematode tissue is needed.

20

In a further aspect, the subject invention provides a method for protecting plants from plant pathogenic nematodes. This method can comprise modifying a plant so that it produces a helper factor.

25

In a further aspect, the subject invention provides a method for preventing or controlling plant pathogenic nematodes by the application to the plant, or the plant's surroundings, a helper factor which facilitates *Pasteuria* growth and/or colonization.

In a preferred embodiment, the subject invention provides a novel method for growing *Pasteuria* bacteria for the production of spores which can then be used as a biocontrol agent for nematodes. In particular, the novel procedure involves the *in vitro* growth of *Pasteuria*.

In a specific embodiment, the method of the subject invention involves growing *Pasteuria* on a nutrient broth (NB). In a preferred embodiment, the *Pasteuria* are grown in the absence of antibiotics and without stirring. Optionally, the NB may be supplemented with bovine calf serum (BCS) and/or an egg yolk preparation.

5 In a specific embodiment of the process of the subject invention, infected female nematodes are washed with water to remove attached debris, soil, microorganisms, etc. Preferably, the washing takes place without disinfectants or antibiotics. The nematodes are then crushed with, for example, slide cover slips which have been sterilized. A small amount of distilled water can be utilized to facilitate the crushing process. Once the crushed
10 nematodes are prepared, they are then introduced into a nutrient medium and grown. This growth can be carried out at room temperature. A standard nutrient broth, optionally supplemented with bovine calf serum, can be utilized. The nutrient broth may also be supplemented with an egg yolk preparation, peanut oil, or other source of lipids. The preparation is permitted to grow, preferably without stirring, at room temperature. Within
15 a period of several hours up to several days, swimming rod-shaped organisms will appear. Production of spores can then be induced as described herein.

In one embodiment of the process of the subject invention, after appearance of motile rods, the preparation can be transferred to a solid growth medium in, for example, a petri dish. Typically, within about 24 hours of growth in the nutrient medium, colonies will
20 appear on the plates (petri dishes). The colonies which appear on the petri dishes comprise the motile rod organisms first observed in the initial growth on nutrient medium. After appearance of the colonies in the nutrient medium, induction of spore formation can be done by, for example, adding manganese sulfate and/or lipids.

In a preferred embodiment of the subject invention, the growth process is carried out
25 to completion in liquid growth medium. This process is simple and highly efficient.

If desired, the helper microorganisms of the subject invention can be separated from the growing *Pasteuria* by a membrane which allows the passage of a chemical helper factor but which blocks the passage of entire microbes. In a specific embodiment, membranes having a pore size of about 0.5 μm can be used to separate the *Pasteuria* from the helper

microbes while permitting the passage of the chemical helper factor. In a more specific embodiment the pore size is 0.45 μm .

Spores will typically form within about 24 hours of spore induction. These spores have been determined to be capable of attaching to J2 juvenile nematodes.

Although not wishing to be bound by theory, it appears that the growth system of the subject invention involves multiple organisms. Thus, for example, the motile rods observed in the nutrient growth media facilitate the optimal growth of the *Pasteuria*. For convenience, reference herein to "helper factor" refers to the motile rods, other microbes, or factors produced by the motile rods or other microbes, which facilitate or enhance the growth of *Pasteuria*. The helper factor(s) are believed to exist internal in the nematodes, or their host plant, and are made available to perform their functions in the system of the subject invention when nematodes are, for example, crushed.

Thus, one aspect of the subject invention is an efficient system for the *in vitro* production of *Pasteuria*. In a preferred embodiment, this system utilizes helper factor(s) to achieve optimal production of *Pasteuria*.

A further aspect of the subject invention pertains to the manipulation of the helper factor(s) of the subject invention to effect control of plant parasitic nematodes. This aspect of the subject invention relates to the involvement of the helper factors in the nematodes' infection of plants. By interfering with the ability of the helper factor to modulate and/or facilitate infection of plants by nematodes it is possible to prevent or inhibit nematode infection of plants. This interference with this function of the helper factor(s) can be achieved by, for example, exposing the helper factors to antibiotics or other agents (such as antisense DNA or RNAi) which inhibit the ability of the helper factor(s) to promote nematode infection (Fire, A., S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello. [1998] "Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*" *Nature* 391:806- 811). Preferably, the inhibiting substance would be present in the roots of the plant.

A further aspect of the subject invention is the use of helper factor(s) to promote efficient colonization and/or infectivity by *Pasteuria*. Thus, live microbial helper factors

such as the motile rods exemplified herein can be applied to the situs of plants to promote the colonization by indigenous *Pasteuria*. Alternatively, microbial helper factors can be mixed with *Pasteuria* and applied to the situs of plants. In a further embodiment, a chemical helper factor, such as HF-1 can be applied with or without contemporaneous application of *Pasteuria*. Helper factors may be applied at the time of planting, either as a seed coat or as a separate composition. Plants may also be transformed to express a chemical helper factor. In a preferred embodiment the helper factor would be expressed in plant roots.

A further aspect of the subject invention pertains to the motile rod organisms which are associated with the ability of the *Pasteuria* to grow *in vitro*. A culture of the microbes has been deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 USA. The deposit has been assigned accession number ATCC No. _____ by the repository.

The subject deposit was deposited under conditions that assure that access to the deposit will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122. The deposit will be available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

Further, the subject deposit will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, *i.e.*, it will be stored with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the culture. The depositor acknowledges the duty to replace the deposit should the depository be unable to furnish a sample when requested, due to the condition of the deposit. All restrictions on the availability to the public of the subject culture deposit will be irrevocably removed upon the granting of a patent disclosing it.

A further aspect of the subject invention pertains to a helper factor of the subject invention designated HF-1. HF-1 is produced by the motile rod isolate described herein and has a size of less than about 0.50 μm . This factor is particularly advantageous because it is associated with the ability of *Pasteuria* to grow *in vitro*.

Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1— Preparation of Nematodes and Growth of *Pasteuria*

Infected Rootknot (*Meloidogyne arenaria*) females were surface washed in autoclaved water. Approximated 100 ml of water were passed over the nematodes in a fine mesh screen. These nematodes were then crushed between autoclaved glass slides in a drop of water. The suspension of material was inoculated into 24 well, sterile plates which contained sterile insect cell culture media (0.5 % glucose and Leibovitz) with 5% Bovine Calf Serum (BSC) added. Growth was observed within 24 hours at room temperature. The growth consisted of motile rods, which was not expected. This material was observed for several days and a few refractile bodies resembling *Pasteuria* endospores appeared. When stained with Gram's Stain the culture contained both negative and positive material. The endospore-like bodies were Gram positive.

Material from agar plates was inoculated into nutrient broth (NB) with BCS. Within 24 hours abundant growth was evident including structures which appeared to be identical to structures found in infected nematodes. In several days refractile bodies filled these structures.

Example 2— Choice of Medium

NB and 0.5 % glucose were the preferred media. Spores produced in the NB attached more readily to the J2's than those produced in 0.5 % glucose. A sterile egg yolk preparation was added to the NB and, within 24 hours, profuse endospores were produced. This media

contained 5% BCS and 5% egg yolk mixture. The spores attached very readily to the J2's. Subsequently, a saturated solution of Wesson's salts were added to the NB and the BCS was eliminated. Again abundant spores were obtained within 24 hours.

The NB media containing the egg yolk and salts was diluted 1:1, 1:5 and 1:10. In all cases growth and spores were obtained. One percent glucose was used with the egg yolk and salts and good growth and spores were obtained within 24 hours.

Subsequently it was determined that the egg yolk mixture could be reduced and that dried egg yolk could be used. The most recent media is either NB (8 g/l) or Glucose (10 g/l) plus 2.5% egg yolk and 5% saturated Wesson Salts. The richness of these media can be reduced if desired.

Example 3 – Primary Culture Isolation

Pasteuria-infected nematodes were harvested from tomato roots 12 to 15 days after inoculating the plants. The nematodes were surface sterilized in 10% Chlorox solution for 5 minutes. From this point aseptic techniques were strictly enforced. Infected nematodes were rinsed twice in 0.6% saline solution. After the final rinse the individual nematodes were placed in wells containing 1 ml Nutrient Broth in a 24-well plate. Using sterile toothpicks, nematodes were crushed to release the vegetative structures of *Pasteuria*. All cultures were incubated at 30°C. The presence of these structures was confirmed using an inverted microscope (400X). Cultures were monitored on a daily basis for the presence of mycelial balls, MB, (vegetative stage of *Pasteuria* growth). Helper factors (contained in 0.45 micron membrane tissue culture inserts) was introduced to some of the cultures 24 hours after initial incubation.

The number and quality of the MB determined the progress in each step. In wells which received no insert, the number of MB and the degree of refractivity decreased as the cultures got older. Almost no MB were present after one week. In the wells which received the helper factor (inserts) for a total of three days, the number of MB increased and the degree of their refractivity remained the same for about 13 days. At this point the MB

morphology changed and their edges became rough. They disappeared from the wells after 15 days. At day 16 mature spores were detected.

Example 4— Attachment of *Pasteuria* Spores to Nematodes

5 Spores harvested from the media described in Example 2 were used for attachment trials on J2 Root knot nematodes using the method described by Dickson. Approximately 1 ml of a suspension containing J2 nematodes was placed in a 1.5 ml centrifuge tube and one drop of the suspension containing the refractile bodies was added. The tubes were spun at 9000 rpm for 3 minutes and the material placed in a well and observed with an inverted
10 microscope. There was clear indication that the refractive bodies were attached to the J2.

 In another experiment, J2's were briefly surface sterilized and then placed in DI water. Spores were then added to the J2's in the wells and attached without centrifugation. Several wells containing J2's with spores attached were observed to determine if the attachments were stable. The wells were examined every day for 10 days and all the
15 attachments were stable. During these observations it was evident that the nematodes would burrow into clumps of matrix material and that the motile rods were still active, even though the only media available was that which was contained in the one drop of spore inoculum added to the 1.5 ml suspension of J2's. After about 14 days, some of the J2's began to molt and after a few more days all of the J2's began to molt.

20 There were several differences with the *in vitro* produced refractile bodies and *in vivo* endospores. The *in vivo* material tended to be very dense concentrations of endospores and included abundant vegetative material mixed with the spores so that a clump of endospores appeared to be attached to the J2's rather than a single spore. However, on closer
25 examination it appeared that one or two spores were attached and the rest were still in the vegetative matrix and were not directly attached to the J2's. Another difference was that, under some circumstances, the *in vitro* endospores appeared slightly smaller.

Example 5— Field Trials

 Several thousand *M. arenaria* J2 nematodes with refractile bodies attached were added to nematode free tomatoes growing in pasteurized soils. After 25 to 30 days the roots

were harvested and examined. Female Rootknot nematodes infected with *Pasteuria* and filled with endospores were recovered.

The tomato experiment was repeated and in all cases female root knot nematodes were recovered which were filled with *Pasteuria penetrans* endospores.

5

Example 6— Identification of Helper Factor(s)

Nutrient broth was inoculated with material from nutrient agar, which had undergone numerous passages. In all cases refractile bodies were observed within a few days. Nucleotide sequence data was obtained from *in vitro* endospores. When compared with sequences of DNA on deposit at GenBank, it was clear that the motile rods were not *Pasteuria* and that there must be two organisms present.

10

A polynucleotide sequence obtained from a motile rod helper factor of the subject invention is shown in SEQ ID NO. 1.

The DNA from the motile rods has 98% homology with *Enterobacter cloacae* and *Pantoea* spp., as well as others.

15

The helper factors of the subject invention include microbes having high sequence similarity to SEQ. ID NO. 1. This high sequence similarity would typically be greater than 50% over a span of at least about 20 bases, preferably greater than 80% and most preferably greater than 90%. Such helper factor microbes can be readily identified by, for example, using SEQ. ID. NO. 1, or fragments thereof, as DNA probes.

20

Example 7 – Polynucleotide probes and primers

DNA possesses a fundamental property called base complementarity. In nature, DNA ordinarily exists in the form of pairs of anti-parallel strands, the bases on each strand projecting from that strand toward the opposite strand. The base adenine (A) on one strand will always be opposed to the base thymine (T) on the other strand, and the base guanine (G) will be opposed to the base cytosine (C). The bases are held in apposition by their ability to hydrogen bond in this specific way. Though each individual bond is relatively weak, the net effect of many adjacent hydrogen bonded bases, together with base stacking effects, is a

25

stable joining of the two complementary strands. These bonds can be broken by treatments such as high pH or high temperature, and these conditions result in the dissociation, or "denaturation," of the two strands. If the DNA is then placed in conditions which make hydrogen bonding of the bases thermodynamically favorable, the DNA strands will anneal, or "hybridize," and reform the original double-stranded DNA. If carried out under appropriate conditions, this hybridization can be highly specific. That is, only strands with a high degree of base complementarity will be able to form stable double-stranded structures. The relationship of the specificity of hybridization to reaction conditions is well known. Thus, hybridization may be used to test whether two pieces of DNA are complementary in their base sequences. It is this hybridization mechanism which facilitates the use of probes of the subject invention to readily detect and characterize DNA sequences of interest.

The specifically exemplified polynucleotides of the subject invention can themselves be used as probes. Additional polynucleotide sequences can be added to the ends of (or internally in) the exemplified polynucleotide sequences so that polynucleotides that are longer than the exemplified polynucleotides can also be used as probes. Thus, isolated polynucleotides comprising one or more of the exemplified sequences are within the scope of the subject invention. Polynucleotides that have less nucleotides than the exemplified polynucleotides can also be used and are contemplated within the scope of the present invention. For example, for some purposes, it might be useful to use a conserved sequence from an exemplified polynucleotide wherein the conserved sequence comprises a portion of an exemplified sequence. Thus, polynucleotides of the subject invention can be used to find additional, homologous (wholly or partially) genes and microbes.

Probes of the subject invention may be composed of DNA, RNA, or PNA (peptide nucleic acid). The probe will normally have at least about 10 bases, more usually at least about 17 bases, and may have about 100 bases or more. Longer probes can readily be utilized, and such probes can be, for example, several kilobases in length. The probe need not have perfect complementarity to the sequence to which it hybridizes. The probes may be labeled utilizing techniques that are well known to those skilled in this art.

One approach for the use of the subject invention as probes entails first identifying DNA segments that are homologous with the disclosed nucleotide sequences using, for example, Southern blot analysis of a gene bank.

One hybridization procedure useful according to the subject invention typically includes the initial steps of isolating the DNA sample of interest and purifying it chemically. Either lysed nematodes (or other parasite hosts, or other samples) or total fractionated nucleic acid isolated from nematodes can be used. Cells can be treated using known techniques to liberate their DNA (and/or RNA). The DNA sample can be cut into pieces with an appropriate restriction enzyme. The pieces can be separated by size through electrophoresis in a gel, usually agarose or acrylamide. The pieces of interest can be transferred to an immobilizing membrane.

The particular hybridization technique is not essential to the subject invention. As improvements are made in hybridization techniques, they can be readily applied.

The probe and sample can then be combined in a hybridization buffer solution and held at an appropriate temperature until annealing occurs. Thereafter, the membrane is washed free of extraneous materials, leaving the sample and bound probe molecules typically detected and quantified by autoradiography and/or liquid scintillation counting. As is well known in the art, if the probe molecule and nucleic acid sample hybridize by forming a strong non-covalent bond between the two molecules, it can be reasonably assumed that the probe and sample are essentially identical or very similar. The probe's detectable label provides a means for determining in a known manner whether hybridization has occurred.

In the use of the nucleotide segments as probes, the particular probe is labeled with any suitable label known to those skilled in the art, including radioactive and non-radioactive labels. Typical radioactive labels include ^{32}P , ^{35}S , or the like. Non-radioactive labels include, for example, ligands such as biotin or thyroxine, as well as enzymes such as hydrolases or peroxidases, or the various chemiluminescers such as luciferin, or fluorescent compounds like fluorescein and its derivatives. In addition, the probes can be made inherently fluorescent as described in International Application No. WO 93/16094.

Various degrees of stringency of hybridization can be employed. The more stringent the conditions, the greater the complementarity that is required for duplex formation. Stringency can be controlled by temperature, probe concentration, probe length, ionic strength, time, and the like. Preferably, hybridization is conducted under moderate to high stringency conditions by techniques well known in the art, as described, for example, in Keller, G.H., M.M. Manak (1987) *DNA Probes*, Stockton Press, New York, NY., pp. 169-170.

As used herein "moderate to high stringency" conditions for hybridization refers to conditions that achieve the same, or about the same, degree of specificity of hybridization as the conditions "as described herein." Examples of moderate to high stringency conditions are provided herein. Specifically, hybridization of immobilized DNA on Southern blots with ³²P-labeled gene-specific probes was performed using standard methods (Maniatis *et al.*). In general, hybridization and subsequent washes were carried out under moderate to high stringency conditions that allowed for detection of target sequences with homology to sequences exemplified herein. For double-stranded DNA gene probes, hybridization was carried out overnight at 20-25° C below the melting temperature (T_m) of the DNA hybrid in 6X SSPE, 5X Denhardt's solution, 0.1% SDS, 0.1 mg/ml denatured DNA. The melting temperature is described by the following formula from Beltz *et al.* (1983):

$$T_m = 81.5^{\circ}\text{C} + 16.6 \log[\text{Na}^+] + 0.41(\%G+C) - 0.61(\%\text{formamide}) - 600/\text{length of duplex in base pairs.}$$

Washes are typically carried out as follows:

- (1) Twice at room temperature for 15 minutes in 1X SSPE, 0.1% SDS (low stringency wash).
- (2) Once at T_m-20°C for 15 minutes in 0.2X SSPE, 0.1% SDS (moderate stringency wash).

For oligonucleotide probes, hybridization was carried out overnight at 10-20°C below the melting temperature (T_m) of the hybrid in 6X SSPE, 5X Denhardt's solution, 0.1% SDS, 0.1 mg/ml denatured DNA. T_m for oligonucleotide probes was determined by the following formula from Suggs *et al.* (1981):

$T_m (^{\circ}\text{C}) = 2(\text{number T/A base pairs}) + 4(\text{number G/C base pairs})$

Washes were typically carried out as follows:

- (1) Twice at room temperature for 15 minutes 1X SSPE, 0.1% SDS (low stringency wash).
- (2) Once at the hybridization temperature for 15 minutes in 1X SSPE, 0.1% SDS (moderate stringency wash).

In general, salt and/or temperature can be altered to change stringency. With a labeled DNA fragment of greater than about 70 or so bases in length, the following conditions can be used:

Low: 1 or 2X SSPE, room temperature

Low: 1 or 2X SSPE, 42°C

Moderate: 0.2X or 1X SSPE, 65°C

High: 0.1X SSPE, 65°C.

Duplex formation and stability depend on substantial complementarity between the two strands of a hybrid, and, as noted above, a certain degree of mismatch can be tolerated.

Therefore, polynucleotide sequences of the subject invention include mutations (both single and multiple), deletions, and insertions in the described sequences, and combinations thereof, wherein said mutations, insertions, and deletions permit formation of stable hybrids with a target polynucleotide of interest. Mutations, insertions, and deletions can be produced in a given polynucleotide sequence using standard methods known in the art. Other methods may become known in the future.

The mutational, insertional, and deletional variants of the polynucleotide sequences of the invention can be used in the same manner as the exemplified polynucleotide sequences so long as the variants have substantial sequence similarity with the original sequence. As used herein, substantial sequence similarity refers to the extent of nucleotide similarity that is sufficient to enable the variant polynucleotide to function in the same capacity as the original sequence. Preferably, this similarity is greater than 50%; more preferably, this similarity is greater than 75%; and most preferably, this similarity is greater than 90%. The degree of similarity needed for the variant to function in its intended capacity will depend upon the intended use of the sequence. It is well within the skill of a person trained in this

art to make mutational, insertional, and deletional mutations that are designed to improve the function of the sequence or otherwise provide a methodological advantage.

5 In a further embodiment, the polynucleotide sequences of the subject invention (and portions thereof such as conserved regions and portions that serve to distinguish these sequences from previously-known sequences) can be used as, and/or used in the design of, primers for PCR amplification. In performing PCR amplification, a certain degree of mismatch can be tolerated between primer and template. Therefore, mutations, deletions, and insertions (especially additions of nucleotides to the 5' end) of the exemplified polynucleotides can be used in this manner. Mutations, insertions and deletions can be
10 produced in a given primer by methods known to an ordinarily skilled artisan.

Other DNA sequences from the motile rod isolate exemplified herein can be used as the basis for DNA probes and/or primers to identify other helper factor microbes and genes.

15 It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

We claim:

1 1. A method for producing *Pasteuria* endospores *in vitro*, said method comprising
2 introducing *Pasteuria* into a growth medium, growing the *Pasteuria* in said growth medium,
3 and obtaining said endospores.

1 2. The method, according to claim 1, wherein said growth medium comprises a
2 helper factor which facilitates the *in vitro* growth of said *Pasteuria*.

1 3. The method, according to claim 2, wherein said helper factor is a microorganism
2 or a chemical compound produced by a microorganism.

1 4. The method, according to claim 3, wherein said microorganism is selected from
2 the group consisting of *Enterobacter cloacae* and *Pantoea* spp.

1 5. The method, according to claim 3, wherein said microorganism has all the
2 identifying characteristics of ATCC _____.

1 6. The method, according to claim 3, wherein said helper factor is a chemical
2 compound produced by said microorganism.

1 7. The method, according to claim 6, wherein said chemical factor passes through
2 a membrane having pores of about 0.5 μm .

1 8. The method, according to claim 7, wherein said chemical factor is HF-1.

1 9. The method, according to claim 1, wherein said growth medium does not
2 comprise an antibiotic.

1 10. The method, according to claim 1, wherein said growing step is carried out
2 without stirring.

1 11. The method according to claim 1, wherein a compound selected from the group
2 consisting of manganese sulfate and lipids is added to induce the production of endospores.

1 12. A method of protecting a plant from infection by nematodes wherein said method
2 comprises applying to the plant, or to the plant's surroundings, a helper factor which
3 promotes the colonization or proliferation of a bacterial nematode biocontrol agent.

1 13. The method, according to claim 12, wherein said substance is a helper factor
2 which promotes the growth of *Pasteuria*.

1 14. The method, according to claim 13, wherein said helper factor is a
2 microorganism, or is a chemical compound produced by a microorganism.

1 15. The method, according to claim 14, wherein said microorganisms is a motile rod.

1 16. The method, according to claim 14, wherein said microorganism is selected from
2 the group consisting of *Enterobacter cloacae* and *Pantoea* spp.

1 17. The method, according to claim 14, wherein said microorganism has all of the
2 identifying characteristics of ATCC _____.

1 18. The method, according to claim 14, wherein said helper factor is a chemical
2 compound produced by a microorganism.

1 19. The method, according to claim 18, wherein said chemical factor passes through
2 a membrane having pores of about $0.5\ \mu\text{m}$.

1 20. The method, according to claim 19, wherein said chemical factor is HF-1.

1 21. The method, according to claim 12, wherein said helper factor is applied to the
2 soil.

1 22. The method, according to claim 12, wherein said helper factor is applied as a
2 seed coating.

1 23. The method, according to claim 12, wherein said plant produces said helper
2 factor.

1 24. The method, according to claim 23, wherein said plant is transformed to express
2 said helper factor.

1 25. The method, according to claim 24, wherein said helper factor is expressed in the
2 roots of said plant.

1 26. A compound designated HF-1 which facilitates the *in vitro* growth of *Pasteuria*,
2 which can be obtained from ATCC _____, and which is less than $50\ \mu\text{m}$ in size.

1 27. A biologically pure culture of the isolate designated ATCC _____.

1 28. An endospore composition produced by the process of claim 1.

- 1
- 2
- 3
- 4

- 1
- 2

[illegible]

Abstract

5

DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name: and

I believe that I am the original, first, and sole inventor (if only one name is listed below), or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **Materials And Methods For The Efficient Production Of *Pasteuria***, specification for which

☐ is attached hereto.

☐ was filed _____, Serial No. _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code §119 and/or §365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Application Serial No.	Country	Filing Date	Priority Claimed

I hereby claim priority benefits under Title 35, United States Code §119 of any provisional application(s) for patent listed below:

Application Serial No.	Filing Date	Priority Claimed
60/148,154	10 August 1999	Yes

I hereby claim the benefit under Title 35, United States Code, §120 and/or §365 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (Patented, Pending, Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following persons registered to practice before the Patent and Trademark Office as my attorneys with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith: David R. Saliwanchik, Reg. No. 31,794; Jeff Lloyd, Reg. No. 35,589; Doran R. Pace, Reg. No. 38,261; Christine Q. McLeod, Reg. No. 36,213; Jay M. Sanders, Reg. No. 39,355; James S. Parker, Reg. No. 40,119; Frank C. Eisenschenk, Reg. No. 45,332; Jean Kyle, Reg. No. 36,987; Seth M. Blum, Reg. No. 45,489; Glenn P. Ladwig, Reg. No. P-46-853.

I request that all correspondence be sent to:

David R. Saliwanchik
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

I further request that all telephone communications be directed to:

David R. Saliwanchik
352-375-8100

Page 2 of 2 pages

SEQUENCE LISTING

<110> Gerber, John

White, James

<120> Materials and Methods for the Efficient Production of Pasteuria

<130> GER-100XC1

<160> 1

<170> PatentIn version 3.0

<210> 1

<211> 1455

<212> DNA

<213> Unknown

<220>

<221> misc_feature

<222> (109)..()

<223> Any nucleotide

<220>

<221> misc_feature

<222> (112)..()

<223> Any nucleotide

<400> 1

ggcaggccta acacatgcaa tcgagcggca gcggaaagta gcttgctact ttgccggcga	60
gcggcggacg ggtgagtaat gtctgggaaa ctacctgang gntggggatc actactggaa	120
acagttgcta ataccgcata acgtctcaag accaaagagg gggaccttcg ggcctcttgc	180
catcagatgt gccagatgg gattagctag taggtggggg aacggctcac ctaggcgacg	240
atccctagct ggtctgagag gatgaccagc cacactggaa ctgagacacg gtccagactc	300
ctacgggagg cagcagtggg gaatattgca caatgggcgc aagcctgatg cagccatgcc	360
gcgtgtatga agaaggcctt cgggttgtaa agtactttca gcggggagga aggcgttgag	420
gttaataacc tcagcgattg acgttaccgc cagaagaagc accggctaac tccgtgccag	480
cagccgcggt aatacggagg gtgcaagcgt taatcggaat tactgggcgt aaagcgcacg	540
caggcgggtct gtcaagtcgg atgtgaaatc cccgggctca acctgggaac tgcattcgaa	600
actggcaggc tagagtcttg tagagggggg tagaattcca ggtgtagcgg tgaaatgcgt	660
agagatctgg aggaataccg gtggcgaagg cggccccctg gacaaagact gacgctcagg	720
tgcgaaagcg tggggagcaa acaggattag ataccctggt agtccacgcc gtaaaccgatg	780
tcgacttgga gggttggtccc ttgaggcgtg gcttccggag ctaacgcgtt aagtcgaccg	840
cctggggagt acggccgcaa ggttaaaact caaatgaatt gacggggggc cgacacaagcg	900
gtggagcatg tggtttaatt cgatgcaacg cgaagaacct tacctactct tgacatccag	960
agaactttcc agagatggat tgggtgccttc gggaactctg agacagggtgc tgcattgctg	1020
tcgtcagctc gtgttggtgaa atgttgggtt aagtcccgcg acgagcgcga cccttatcct	1080
ttgttgccag cggttaggcc gggaaactcaa aggagactgc cagtgataaa ctggaggaag	1140
gtgggggatga cgtcaagtca tcatggccct tacgagtagg gctacacacg tgctacaatg	1200
gcgcatacaa agagaagcga cctcgcgaga gcaagcggac ctcataaagt gcgtcgtagt	1260

ccggattgga gtctgcaact cgactccatg aagtcggaat cgctagtaat cgtagatcag	1320
aatgctacgg tgaatacgtt cccggggcctt gtacacaccg cccgtaaggg cgaattctgc	1380
agatatccat cacactggcg gccgctcgag cagcatctag agggcccaat tcgccctata	1440
gtgagtcgta ttaca	1455

[illegible]